Skip to Content
Merck
  • Type I Interferons Act Directly on Nociceptors to Produce Pain Sensitization: Implications for Viral Infection-Induced Pain.

Type I Interferons Act Directly on Nociceptors to Produce Pain Sensitization: Implications for Viral Infection-Induced Pain.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2020-04-05)
Paulino Barragán-Iglesias, Úrzula Franco-Enzástiga, Vivekanand Jeevakumar, Stephanie Shiers, Andi Wangzhou, Vinicio Granados-Soto, Zachary T Campbell, Gregory Dussor, Theodore J Price
ABSTRACT

One of the first signs of viral infection is body-wide aches and pain. Although this type of pain usually subsides, at the extreme, viral infections can induce painful neuropathies that can last for decades. Neither of these types of pain sensitization is well understood. A key part of the response to viral infection is production of interferons (IFNs), which then activate their specific receptors (IFNRs) resulting in downstream activation of cellular signaling and a variety of physiological responses. We sought to understand how type I IFNs (IFN-α and IFN-β) might act directly on nociceptors in the dorsal root ganglion (DRG) to cause pain sensitization. We demonstrate that type I IFNRs are expressed in small/medium DRG neurons and that their activation produces neuronal hyper-excitability and mechanical pain in mice. Type I IFNs stimulate JAK/STAT signaling in DRG neurons but this does not apparently result in PKR-eIF2α activation that normally induces an anti-viral response by limiting mRNA translation. Rather, type I IFNs stimulate MNK-mediated eIF4E phosphorylation in DRG neurons to promote pain hypersensitivity. Endogenous release of type I IFNs with the double-stranded RNA mimetic poly(I:C) likewise produces pain hypersensitivity that is blunted in mice lacking MNK-eIF4E signaling. Our findings reveal mechanisms through which type I IFNs cause nociceptor sensitization with implications for understanding how viral infections promote pain and can lead to neuropathies.SIGNIFICANCE STATEMENT It is increasingly understood that pathogens interact with nociceptors to alert organisms to infection as well as to mount early host defenses. Although specific mechanisms have been discovered for diverse bacterial and fungal pathogens, mechanisms engaged by viruses have remained elusive. Here we show that type I interferons, one of the first mediators produced by viral infection, act directly on nociceptors to produce pain sensitization. Type I interferons act via a specific signaling pathway (MNK-eIF4E signaling), which is known to produce nociceptor sensitization in inflammatory and neuropathic pain conditions. Our work reveals a mechanism through which viral infections cause heightened pain sensitivity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
DL-Kynurenine, ≥95.0% (NT)
Sigma-Aldrich
Anti-Peripherin Antibody, clone 8G2, culture supernatant, clone 8G2, Chemicon®
Sigma-Aldrich
ISRIB, ≥98% (HPLC)
Sigma-Aldrich
Polyinosinic–polycytidylic acid sodium salt, TLR ligand tested
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
Interferon-β Protein, Recombinant mouse, Interferon-β Protein, Recombinant mouse.
Sigma-Aldrich
Anti-NeuN Antibody, clone A60, clone A60, Chemicon®, from mouse